SI0959888T1 - Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease - Google Patents

Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Info

Publication number: SI0959888T1
Authority: SI; Slovenia
Prior art keywords: pharmaceutical composition; alzheimer; disease; manufacture; treatment
Prior art date: 1996-08-13

Application number

SI9730230T

Other languages

English (en)

Slovenian (sl)

Inventor

Panayotis Nikolas Gerolymatos

Original Assignee

P. N. Gerolymatos S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-13

Filing date

1997-08-08

Publication date

2002-10-31

1997-08-08 Application filed by P. N. Gerolymatos S.A. filed Critical P. N. Gerolymatos S.A.

2002-10-31 Publication of SI0959888T1 publication Critical patent/SI0959888T1/xx

Links

QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 title abstract 3
229960005228 clioquinol Drugs 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
208000024827 Alzheimer disease Diseases 0.000 title 1
239000002738 chelating agent Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
229930003779 Vitamin B12 Natural products 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000011715 vitamin B12 Substances 0.000 abstract 1
235000019163 vitamin B12 Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)

SI9730230T 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease SI0959888T1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GR96100286		1996-08-13
EP97932969A EP0959888B1 (fr)	1996-08-13	1997-08-08	Emploi du chelateur clioquinol pour produire une preparation pharmaceutique traitant la maladie d'alzheimer
PCT/IB1997/000983 WO1998006403A1 (fr)	1996-08-13	1997-08-08	Emploi du chelateur clioquinol pour produire une preparation pharmaceutique traitant la maladie d'alzheimer

Publications (1)

Publication Number	Publication Date
SI0959888T1 true SI0959888T1 (en)	2002-10-31

Family

ID=10942479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9730230T SI0959888T1 (en)	1996-08-13	1997-08-08	Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Country Status (25)

Country	Link
US (1)	US6001852A (fr)
EP (1)	EP0959888B1 (fr)
JP (1)	JP2000516606A (fr)
KR (1)	KR100489969B1 (fr)
CN (1)	CN1114407C (fr)
AT (1)	ATE205086T1 (fr)
AU (1)	AU720643B2 (fr)
BR (1)	BR9711194A (fr)
CA (1)	CA2264097C (fr)
CZ (2)	CZ295118B6 (fr)
DE (1)	DE69706566T2 (fr)
DK (1)	DK0959888T3 (fr)
ES (1)	ES2162319T3 (fr)
HU (1)	HUP9903906A3 (fr)
IL (1)	IL128416A (fr)
IS (1)	IS1907B (fr)
NO (1)	NO316768B1 (fr)
NZ (1)	NZ334124A (fr)
PL (1)	PL188838B1 (fr)
PT (1)	PT959888E (fr)
RU (1)	RU2193406C2 (fr)
SI (1)	SI0959888T1 (fr)
SK (1)	SK283117B6 (fr)
TR (1)	TR199900293T2 (fr)
WO (1)	WO1998006403A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045531B1 (en)	1997-03-11	2006-05-16	The General Hospital Corporation	Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6670369B1 (en) *	1997-08-21	2003-12-30	P.N. Gerolymatos S.A.	Use of phanquinone for the treatment of alzheimer's disease
AU760140B2 (en) *	1997-10-24	2003-05-08	John P. Blass	Nutritional supplement for cerebral metabolic insufficiencies
US5994323A (en) *	1997-12-31	1999-11-30	P.N. Gerolymatos S.A.	Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US20020025944A1 (en) *	2000-04-28	2002-02-28	Bush Ashley I.	Use of clioquinol for the therapy of Alzheimer's disease
US6323218B1 (en) *	1998-03-11	2001-11-27	The General Hospital Corporation	Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en)	1999-04-29	2003-10-28	The General Hospital Corporation	Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US20050112543A1 (en) *	1998-03-11	2005-05-26	The General Hospital Corporation	Method of screening for drugs useful in treating Alzheimer's disease
DE60016892T2 (de)	1999-01-07	2005-12-15	P.N. Gerolymatos S.A., Kryoneri	Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
US6692234B2 (en)	1999-03-22	2004-02-17	Water Management Systems	Pump system with vacuum source
HUP0204474A3 (en) *	2000-02-09	2004-07-28	Hokuriku Pharmaceutical	1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
FR2818551B1 (fr) *	2000-12-22	2007-06-01	Claude Marc Pierre Hannoun	Utilisation de chelateurs pour le traitement des maladies a prions
US6803379B2 (en) *	2002-06-04	2004-10-12	Jose A. Fernandez-Pol	Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en) *	2002-07-16	2002-09-12	Prana Biotechnology Limited	8- Hydroxy Quinoline Derivatives
EP1558585B1 (fr) *	2002-10-04	2013-09-25	Prana Biotechnology Limited	Composes neurologiquement actifs
US20080063599A1 (en) *	2002-11-18	2008-03-13	Jorge Setoain Quinquer	Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
AU2004226876A1 (en) *	2003-04-03	2004-10-14	Prana Biotechnology Ltd	Treatment of neurological conditions
US20070275943A1 (en) *	2003-11-19	2007-11-29	Acrux Dds Pty Ltd.	Method and Composition for Treatment or Prophylaxis of Amyloidosis Disorders
US20060194723A1 (en) *	2005-02-28	2006-08-31	Rabinoff Michael D	Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
CN102764279B (zh) *	2005-10-14	2015-04-01	全面技术公司	改变细胞功能的方法和组合物
US8865763B2 (en)	2005-10-14	2014-10-21	Alltech, Inc.	Methods and compositions for altering cell function
US8871715B2 (en)	2005-10-14	2014-10-28	Alltech, Inc.	Use of selenium compounds, especially selenium yeasts for altering cognitive function
AU2006319358B2 (en) *	2005-11-30	2012-01-19	AbbVie Deutschland GmbH & Co. KG	Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8497072B2 (en) *	2005-11-30	2013-07-30	Abbott Laboratories	Amyloid-beta globulomer antibodies
US20100144693A1 (en) *	2006-04-14	2010-06-10	Prana Biotechnology Limited	Method of treatment of age-related macular degeneration (amd)
RS53160B (en) *	2006-07-14	2014-06-30	Ac Immune S.A.	HUMANIZED BETA AMILOID ANTIBODY
PL2468770T3 (pl) *	2006-07-14	2018-07-31	Ac Immune S.A.	Humanizowane przeciwciało przeciw amyloidowi beta
RU2338542C1 (ru) *	2007-03-20	2008-11-20	Игорь Анатольевич Помыткин	Применение воды с пониженным содержанием дейтерия для приготовления средств лечения нейродегенеративных заболеваний и улучшения когнитивной функции
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
EP2238166B1 (fr)	2007-10-05	2013-11-27	Genentech, Inc.	Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
ES2332687B1 (es) *	2008-03-13	2011-01-10	Proyecto De Biomedicina Cima, S.L.	Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
US9221900B2 (en)	2010-07-30	2015-12-29	Ac Immune S.A.	Methods for identifying safe and functional humanized antibodies
FR2966827B1 (fr)	2010-10-27	2014-08-22	Kimonella Ventures Ltd	Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
AU2013385618B2 (en) *	2013-04-02	2017-01-05	Annji Pharmaceutical Co., Ltd.	Multifunctional quinoline derivatives as anti-neurodegenerative agents
JP6461922B2 (ja)	2014-04-24	2019-01-30	想い出創造株式会社	アミロイド線維形成の抑制又は阻害剤
KR20160057500A (ko) *	2014-11-05	2016-05-24	아카데미아 시니카	클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE393238C (de) *	1923-05-12	1924-03-31	Maschb Akt Ges H Flottmann & C	Bohrhammer
US3174899A (en) *	1960-12-30	1965-03-23	Ciba Geigy Corp	Composition for the management of post antibiotic enteritis
US3178343A (en) *	1962-11-27	1965-04-13	Ciba Geigy Corp	Pharmaceutical compositions and method of using same
DE1617417A1 (de) *	1966-12-08	1971-03-25	Ciba Geigy	Pharmazeutisches Praeparat
RU2057531C1 (ru) *	1986-07-01	1996-04-10	Всероссийский научный центр по безопасности биологически активных веществ	Средство для стимуляции обучения и памяти
DE3932338A1 (de) *	1989-09-28	1991-04-11	Nmi Naturwissenschaftl U Mediz	Verfahren zur praeventiven therapie von morbus alzheimer
GB9010039D0 (en) *	1990-05-03	1990-06-27	Reckitt & Colmann Prod Ltd	Medicament preparation
GB9108080D0 (en) *	1991-04-15	1991-06-05	Smithkline Beecham Plc	Pharmaceutical composition
US5206264A (en) *	1991-11-04	1993-04-27	Cypros Pharmaceutical Corporation	Use of disulfiram to prevent cardiovascular damage
US5705401A (en) *	1991-11-12	1998-01-06	The University Of Melbourne	Method of assaying for alzheimer's disease
US5607691A (en) *	1992-06-12	1997-03-04	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
WO1995019178A1 (fr) *	1994-01-13	1995-07-20	Research Foundation For Mental Hygiene, Inc.	Procedes et compositions de traitement et de diagnostic de la maladie d'alzheimer et d'autres troubles
WO1995031199A1 (fr) *	1994-05-11	1995-11-23	P.N. Gerolymatos S.A.	Utilisation de clioquinol dans le traitement d'infections provoquees par helicobacter, y compris h. pylori et de maladies apparentees
US5505958A (en) *	1994-10-31	1996-04-09	Algos Pharmaceutical Corporation	Transdermal drug delivery device and method for its manufacture

1997
- 1997-08-08 JP JP10509541A patent/JP2000516606A/ja active Pending
- 1997-08-08 RU RU99105213/14A patent/RU2193406C2/ru not_active IP Right Cessation
- 1997-08-08 BR BR9711194-5A patent/BR9711194A/pt not_active Application Discontinuation
- 1997-08-08 HU HU9903906A patent/HUP9903906A3/hu unknown
- 1997-08-08 WO PCT/IB1997/000983 patent/WO1998006403A1/fr active IP Right Grant
- 1997-08-08 NZ NZ334124A patent/NZ334124A/xx unknown
- 1997-08-08 KR KR10-1999-7001196A patent/KR100489969B1/ko not_active Expired - Fee Related
- 1997-08-08 AT AT97932969T patent/ATE205086T1/de not_active IP Right Cessation
- 1997-08-08 EP EP97932969A patent/EP0959888B1/fr not_active Expired - Lifetime
- 1997-08-08 CN CN97197919A patent/CN1114407C/zh not_active Expired - Fee Related
- 1997-08-08 PL PL97331822A patent/PL188838B1/pl not_active IP Right Cessation
- 1997-08-08 ES ES97932969T patent/ES2162319T3/es not_active Expired - Lifetime
- 1997-08-08 CZ CZ2003491A patent/CZ295118B6/cs not_active IP Right Cessation
- 1997-08-08 PT PT97932969T patent/PT959888E/pt unknown
- 1997-08-08 CA CA002264097A patent/CA2264097C/fr not_active Expired - Fee Related
- 1997-08-08 SK SK179-99A patent/SK283117B6/sk not_active IP Right Cessation
- 1997-08-08 DK DK97932969T patent/DK0959888T3/da active
- 1997-08-08 DE DE69706566T patent/DE69706566T2/de not_active Expired - Lifetime
- 1997-08-08 CZ CZ1999484A patent/CZ292411B6/cs not_active IP Right Cessation
- 1997-08-08 IL IL12841697A patent/IL128416A/en not_active IP Right Cessation
- 1997-08-08 SI SI9730230T patent/SI0959888T1/xx unknown
- 1997-08-08 TR TR1999/00293T patent/TR199900293T2/xx unknown
- 1997-08-08 AU AU36324/97A patent/AU720643B2/en not_active Ceased
1998
- 1998-02-13 US US09/023,544 patent/US6001852A/en not_active Expired - Lifetime
1999
- 1999-02-09 NO NO19990595A patent/NO316768B1/no not_active Application Discontinuation
- 1999-02-10 IS IS4972A patent/IS1907B/is unknown

Also Published As

Publication number	Publication date
CN1230115A (zh)	1999-09-29
PL188838B1 (pl)	2005-04-29
HUP9903906A2 (hu)	2000-04-28
NO990595D0 (no)	1999-02-09
WO1998006403A1 (fr)	1998-02-19
PT959888E (pt)	2002-02-28
RU2193406C2 (ru)	2002-11-27
DE69706566T2 (de)	2002-07-11
DE69706566D1 (de)	2001-10-11
SK283117B6 (sk)	2003-02-04
IS1907B (is)	2003-12-16
PL331822A1 (en)	1999-08-02
NO990595L (no)	1999-04-12
IL128416A0 (en)	2000-01-31
CA2264097A1 (fr)	1998-02-19
EP0959888B1 (fr)	2001-09-05
ATE205086T1 (de)	2001-09-15
IS4972A (is)	1999-02-10
US6001852A (en)	1999-12-14
AU3632497A (en)	1998-03-06
HUP9903906A3 (en)	2001-01-29
CZ48499A3 (cs)	1999-07-14
SK17999A3 (en)	1999-09-10
NO316768B1 (no)	1999-04-12
CZ292411B6 (cs)	2003-09-17
BR9711194A (pt)	2000-01-11
JP2000516606A (ja)	2000-12-12
AU720643B2 (en)	2000-06-08
CA2264097C (fr)	2007-11-27
IL128416A (en)	2004-06-01
NZ334124A (en)	2000-10-27
DK0959888T3 (da)	2001-11-05
CN1114407C (zh)	2003-07-16
CZ295118B6 (cs)	2005-05-18
KR20000029958A (ko)	2000-05-25
ES2162319T3 (es)	2001-12-16
TR199900293T2 (xx)	1999-06-21
KR100489969B1 (ko)	2005-05-17
HK1022437A1 (en)	2000-08-11
EP0959888A1 (fr)	1999-12-01

Publication	Publication Date	Title
SI0959888T1 (en)	2002-10-31	Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MY127980A (en)	2007-01-31	A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002225772A1 (en)	2002-06-03	Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HUP0000558A3 (en)	2000-12-28	Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
MY118526A (en)	2004-11-30	Method for improving the pharmacokinetics of tipranavir
GB9103764D0 (en)	1991-04-10	Compositions
IL134263A0 (en)	2001-04-30	Use of phanquinone for the treatment of alzheimer's disease
BG102667A (en)	1999-02-26	Diosgenine-containing composition
MX9707642A (es)	1997-12-31	Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
DK0583026T3 (fr)	1997-02-24
IL105475A (en)	1997-06-10	PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
AU1656997A (en)	1997-10-02	Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MXPA02011533A (es)	2003-04-25	Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
AUPP823999A0 (en)	1999-02-11	A treatment
BG106151A (en)	2002-05-31	Pharmaceutical complex
UA29461C2 (uk)	2000-11-15	Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
HUP9802536A3 (en)	2000-02-28	Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer
ZA924128B (en)	1993-03-25	New combination preparations for treatment of Parkinson's disease.
NZ268039A (en)	1999-06-29	Use of efaroxan in treating parkinson's disease
GEP20094628B (en)	2009-03-10	(s,s)-reboxetine for treating fibromyalgia and other somatoform disorders
MX9709684A (es)	1998-06-28	Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.